SCHEMBL6678339

SCHEMBL6678339

COc1cccc(CNC(=O)C2=Cn3c(c(C)c(=O)n(Cc4ccccc4)c3=O)CN2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
TRPA1 O75762 2/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
USP2 O75604 1/20 0.45
MMP13 P45452 1/20 0.44
PPARG P37231 1/20 0.43
RAB9A P51151 1/20 0.43
NR3C2 P08235 1/20 0.43
TOP2A P11388 1/20 0.43
TP53 P04637 6/20 0.43
RXFP1 Q9HBX9 3/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
APEX1 P27695 1/20 0.42
ENPP2 Q13822 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6665653 0.85 MMP1 (0.43) MAPTKDM4EALDH1A1RAB9ATP53
SCHEMBL6683643 0.83 MAPT (0.53) MAPTTRPA1KDM4EALDH1A1HPGD
SCHEMBL6718675 0.83 MAPT (0.51) MAPTTRPA1KDM4EALDH1A1HPGD
SCHEMBL6684992 0.79 TRPA1 (0.39) TRPA1KDM4EHPGDRAB9ALMNA
SCHEMBL6679307 0.76 TRPA1 (0.43) MAPTTRPA1ALDH1A1HPGDTP53
SCHEMBL5957675 0.73 TRPA1 (0.79) MAPTTRPA1RAB9ANR3C2TP53
SCHEMBL6682687 0.72 MAPT (0.46) MAPTTRPA1KDM4EALDH1A1HPGD
SCHEMBL6681435 0.72 THRB (0.43) MAPTKDM4EALDH1A1RAB9ATP53
SCHEMBL6718409 0.72 THRB (0.43) MAPTKDM4EALDH1A1RAB9ATP53
SCHEMBL7120798 0.70 MAPT (0.49) MAPTKDM4EALDH1A1HPGDUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US claimed
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP11 MAPT 1535/4885TRPA1 4681/4885KDM4E 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.